Company: AZN
Filing Date: 2025-10-07
Form Type: 6-K
Source: 0001654954-25-011529
Chunk: 3

Company: ASTRAZENECA PLC
Filing Date: 2025-10-07
Form: 6-K
Chunk 3
---
 with rHTN. A total of 218 patients were randomised in a 1:1 ratio to receive baxdrostat 2mg or placebo once daily during a 12-week double blind period. The primary efficacy endpoint was the change from baseline in ambulatory 24-hour average SBP at Week 12.

Additional secondary endpoints include the effect of baxdrostat versus placebo on change from baseline in ambulatory night-time average SBP at Week 12, change from baseline in ambulatory daytime average SBP at Week 12, change from baseline in seated SBP at Week 12, the number of participants achieving ambulatory 24-hour average SBP of less than 130 mmHg at Week 12 and the number of participants achieving a nocturnal SBP dipping of greater than 10% at Week 12. Occurrence of adverse events was evaluated during the 12-week treatment period as well as during a 2-week safety follow-up period.

#### Baxdrostat
Baxdrostat is a potential first-in-class, highly selective and potent, oral, small molecule that inhibits aldosterone synthase, 11 an enzyme encoded by the CYP11B2 gene, which is responsible for the synthesis of aldosterone in the adrenal gland. 23 In clinical trials, baxdrostat was observed to significantly lower aldosterone levels without affecting cortisol levels across a wide range of doses. 12,26 Baxdrostat is currently being investigated in clinical trials as a monotherapy for hypertension 13-15 and primary aldosteronism, 16 and in combination with dapagliflozin for chronic kidney disease and hypertension, 17,18 and the prevention of heart failure in patients with hypertension. 19

AstraZeneca acquired baxdrostat through its purchase of CinCor Pharma, Inc. in February 2023. 27

AstraZeneca in CVRM

Cardiovascular, Renal and Metabolism (CVRM), part of BioPharmaceuticals, forms one of AstraZeneca's main disease areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys, liver and pancreas, AstraZeneca is investing in a portfolio of medicines for organ protection by slowing or stopping disease progression, and ultimately paving the way towards regenerative therapies. The Company's ambition is to improve and save the lives of millions of people, by better understanding the inter